| pubmed-article:11844695 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11844695 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:11844695 | lifeskim:mentions | umls-concept:C0061352 | lld:lifeskim |
| pubmed-article:11844695 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:11844695 | lifeskim:mentions | umls-concept:C1705938 | lld:lifeskim |
| pubmed-article:11844695 | lifeskim:mentions | umls-concept:C1527178 | lld:lifeskim |
| pubmed-article:11844695 | lifeskim:mentions | umls-concept:C0682951 | lld:lifeskim |
| pubmed-article:11844695 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11844695 | pubmed:dateCreated | 2002-2-14 | lld:pubmed |
| pubmed-article:11844695 | pubmed:abstractText | A series of alkylidene hydrazide derivatives containing an alkoxyaryl moiety was optimized. The resulting hydrazide-ethers were competitive antagonists at the human glucagon receptor. Pharmacokinetic experiments showed fast clearance of most of the compounds tested. A representative compound [4-hydroxy-3-cyanobenzoic acid (4-isopropylbenzyloxy-3,5-dimethoxymethylene)hydrazide] with an IC50 value of 20 nM was shown to reduce blood glucose levels in fasted rats. | lld:pubmed |
| pubmed-article:11844695 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11844695 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11844695 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11844695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11844695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11844695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11844695 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11844695 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11844695 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11844695 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:MayJohnJ | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:BrandChristia... | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:LingAnthonyA | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:PleweMichaelM | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:GonzalezJavie... | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:MadsenPeterP | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:SamsChristian... | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:LauJesperJ | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:GregorVladV | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:MurphyDougD | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:TestonKimberl... | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:KukiAtsuoA | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:ShiShenghuaS | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:TruesdaleLarr... | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:KielDanD | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:LakisJamesJ | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:AnderesKennaK | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:Iatsimirskaia... | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:SidelmannUlla... | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:KnudsenLotte... | lld:pubmed |
| pubmed-article:11844695 | pubmed:author | pubmed-author:PolinskyAlexA | lld:pubmed |
| pubmed-article:11844695 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11844695 | pubmed:day | 25 | lld:pubmed |
| pubmed-article:11844695 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:11844695 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11844695 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11844695 | pubmed:pagination | 663-6 | lld:pubmed |
| pubmed-article:11844695 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:meshHeading | pubmed-meshheading:11844695... | lld:pubmed |
| pubmed-article:11844695 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11844695 | pubmed:articleTitle | Human glucagon receptor antagonists based on alkylidene hydrazides. | lld:pubmed |
| pubmed-article:11844695 | pubmed:affiliation | Pfizer Global Research and Development, 10770 Science Center Dr., San Diego, CA 92121, USA. anthony.ling@agouron.com | lld:pubmed |
| pubmed-article:11844695 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:11844695 | lld:chembl |
